New partnership aims to advance vaccine against MERS coronavirus
21 déc. 2023 07h31 HE
|
Barinthus Biotherapeutics
CEPI to invest funding of up to $34.8 million to Barinthus Bio in addition to funds previously committed to University of Oxford to develop VTP-500
Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors
01 juin 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., June 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National...
Co-Diagnostics (NASDAQ:CODX) Prepares Coronavirus Test as World Health Organization Weighs Global Health Emergency
23 janv. 2020 15h05 HE
|
BDA International
New York City, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Shares of Co-Diagnostics, Inc. (Nasdaq:CODX), a biotech company with a patented platform for the development of molecular diagnostic tests, leaped...
Hemispherx Biopharma Enters into Alfa-n3 Interferon Clinical Trial, Sales, Marketing, Distribution, and Supply Agreement with Saudi Arabia’s Premier Pharma Company in Fight Against the Deadly MERS Disease
04 avr. 2016 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, April 04, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the Company) announced today that it has entered into a Clinical Trial, Sales, Marketing, Distribution,...
Hemispherx Biopharma Europe N.V./S.A. : Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Alferon N Injection® as a Treatment of Middle East Respiratory Syndrome (MERS)
20 janv. 2016 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the “Company” or “Hemispherx”) announces that the European Medicines Agency (EMA) on January 6, 2016 has...
Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Alferon N Injection to Treat Patients With Middle East Respiratory Syndrome (MERS)
19 oct. 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Oct. 19, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announces that the European subsidiary, “Hemispherx Biopharma Europe...
To Address Future Infectious Disease Outbreaks, North Shore-LIJ Announces Plans to Build Bio-Containment Unit
23 oct. 2014 10h29 HE
|
North Shore Long Island Jewish Health System
MANHASSET, N.Y., Oct. 23, 2014 (GLOBE NEWSWIRE) -- The North Shore-LIJ Health System announced today it will pursue the development of a biological containment unit to further improve its preparedness...
Hemispherx Biopharma and the Swiss Department of Defense, Civil Protection and Sports Expand Their Collaborative Research Agreement to Include the Study of Alferon(R) and Ampligen(R) Against the Ebola Virus
10 sept. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 10, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced that it expanded its Collaborative Research Agreement to test...
Hemispherx Biopharma Announces Financial Results for the Six Months Ended June 30, 2014
11 août 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the six months ended June 30, 2014. The net loss (including non-cash effects) was...
Hemispherx's Two Drugs, Ampligen(R) and Alferon(R) Ranked Highly in Sensitivity Testing Against MERS/SARS Coronaviruses
04 août 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Aug. 4, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a peer-reviewed electronic publication entitled "Sensitivity of SARS/MERS CoV to Interferons and...